Engineered cell treatments, such as CAR-T cell cancer immunotherapies and hematopoietic stem cell gene therapies, are extremely expensive. In large part that is because it’s not easy to grow myriads of precisely engineered cells that are originally sourced from the patient being treated.
Now, researchers at University of California, Rive (Read more...)